Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by mol...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancers (Basel)
Main Authors: Hofman, Véronique, Lassalle, Sandra, Bence, Coraline, Long-Mira, Elodie, Nahon-Estève, Sacha, Heeke, Simon, Lespinet-Fabre, Virginie, Butori, Catherine, Ilié, Marius, Hofman, Paul
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2018
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5876645/
https://ncbi.nlm.nih.gov/pubmed/29534030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10030070
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki